A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 108
- Registration Number
- NCT04900363
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 50
- Registration Number
- NCT04868708
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of AK112 in the Treatment of Advanced Gynecological Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 270
- Registration Number
- NCT04870177
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, China
🇨🇳Qilu Hospital of Shandong University, Qilu, Shandong, China
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 28
- Registration Number
- NCT04736810
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Akeso
- Target Recruit Count
- 296
- Registration Number
- NCT04736823
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China
A Phase 1 Dose Escalation and Expansion Study of AK117
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Akeso
- Target Recruit Count
- 49
- Registration Number
- NCT04728334
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 32
- Registration Number
- NCT04728321
- Locations
- 🇨🇳
The first affilited hospital zhejiang university school of medcine, Hangzhou, Zhejiang, China
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 46
- Registration Number
- NCT04647344
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guanzhou, Guangdong, China
A Trial of AK104 Plus Anlotinib in NSCLC
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT04646330
- Locations
- 🇨🇳
Hunan cancer hospital, Changsha, Hunan, China
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Akeso
- Target Recruit Count
- 59
- Registration Number
- NCT04597541
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China